Previous 10 | Next 10 |
Compugen Presents New Research Data Further Supporting PVRIG as a Potentially Promising Target for Cancer Immunotherapy Expression data suggest potential of PVRIG inhibition to enhance T cell priming and infiltration into both inflamed and less inflamed tumors Data further s...
Compugen to Release Third Quarter 2020 Results on Thursday, November 5, 2020 PR Newswire HOLON, Israel, Oct. 22, 2020 HOLON, Israel , Oct. 22, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a lead...
Compugen Announces Addition of Immuno-oncology Pioneer Dr. Nils Lonberg to its Scientific Advisory Board PR Newswire HOLON, Israel, Sept. 30, 2020 HOLON, Israel , Sept. 30, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer imm...
Despite its recent share price increase, Evogene continues to be undervalued given the sum of parts valuation of its 4 main subsidiaries and $45 million cash position. Evogene is a computational biology company. This article is Part 4 of a 4 part series which will focus on Evogene's w...
Dosing is underway in Compugen's ( CGEN -3.1% ) Phase 1/2 study evaluating the triple combination of Compugen's COM701, with Bristol Myers Squibb's Opdivo (nivolumab), and their investigational anti-TIGIT antibody, BMS-986207, for solid tumors. More news on: Compugen Ltd., Heal...
HOLON, Israel , Sept. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the Phase 1/2 study evaluating the triple combination...
HOLON, Israel , Sept. 3, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the following upcoming virtual investor conferences:...
This is the 3rd article in a 4-part series on Israel-based Evogene Ltd. ( EVGN ). This article will focus on Evogene's 100% owned subsidiary AgPlenus. For more information about Evogene, I invite you to read the first two articles in this 4-part Evogene series which were published on Seeking...
The USPTO has granted Compugen (NASDAQ: CGEN ) a new patent for COM902, its immuno-oncology therapeutic antibody targeting TIGIT. More news on: Compugen Ltd., Healthcare stocks news, Read more ...
HOLON, Israel , Aug. 28, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted a new patent covering the comp...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...